← All trials
NCT03488810
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2018
- Primary completion
- Jun 15, 2026
- Completion date
- Jun 15, 2026
- First posted
- —
- Last posted
- —
- Enrollment
- 990
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- European Organisation for Research and Treatment of CancerLead sponsor
- Grenoble Alps UniversityOverall official - principal investigator
- Centre Georges Francois LeclercOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.